Healthcare provider profile · identity verified

Jeffrey David Martens, MD

Internal Medicine · YARMOUTH PORT, MA · NPI 1063485795

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	251	70
Lisinopril	Lisinopril	229	60
Amlodipine Besylate	Amlodipine Besylate	199	61
Levothyroxine Sodium	Levothyroxine Sodium	176	49
Metoprolol Succinate	Metoprolol Succinate	172	46
Simvastatin	Simvastatin	130	30
Omeprazole	Omeprazole	116	34
Pantoprazole Sodium	Pantoprazole Sodium	103	29
Metformin Hcl	Metformin Hcl	99	24
Tamsulosin Hcl	Tamsulosin Hcl	89	29
Losartan Potassium	Losartan Potassium	87	27
Gabapentin	Gabapentin	78	22
Rosuvastatin Calcium	Rosuvastatin Calcium	76	22
Escitalopram Oxalate	Escitalopram Oxalate	70	24
Valsartan	Valsartan	66	17
Trazodone Hcl	Trazodone Hcl	60	18
Olmesartan Medoxomil	Olmesartan Medoxomil	59	16
Tramadol Hcl	Tramadol Hcl	59	18
Lorazepam	Lorazepam	53	16
Albuterol Sulfate Hfa	Albuterol Sulfate	52	23
Sertraline Hcl	Sertraline Hcl	49	15
Alendronate Sodium	Alendronate Sodium	45	12
Furosemide	Furosemide	41	13
Allopurinol	Allopurinol	39	11
Carvedilol	Carvedilol	35	suppressed
Clopidogrel	Clopidogrel Bisulfate	35	12
Eliquis	Apixaban	33	suppressed
Prednisone	Prednisone	33	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	33	suppressed
Atenolol	Atenolol	32	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	32	13
Januvia	Sitagliptin Phosphate	32	suppressed
Alprazolam	Alprazolam	31	suppressed
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Fluticasone Propionate	Fluticasone Propionate	27	12
Xarelto	Rivaroxaban	27	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	26	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Finasteride	Finasteride	25	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Oxycodone Hcl	Oxycodone Hcl	24	13
Amoxicillin	Amoxicillin	23	19
Synthroid	Levothyroxine Sodium	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Azithromycin	Azithromycin	19	17
Buspirone Hcl	Buspirone Hcl	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Pregabalin	Pregabalin	19	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	17	suppressed
Montelukast Sodium	Montelukast Sodium	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	11
Ibuprofen	Ibuprofen	14	suppressed
Ramipril	Ramipril	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Desmopressin Acetate	Desmopressin Acetate	13	suppressed
Dexlansoprazole Dr	Dexlansoprazole	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Buprenorphine	Buprenorphine	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Linzess	Linaclotide	12	suppressed
Oxycontin	Oxycodone Hcl	12	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Risperidone	Risperidone	11	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error